A review of smoking cessation: potentially risky effects on prescribed medications

Schaffer, Susan D.; Yoon, Saunjoo L.; Zadezensky, Immo

doi:10.1111/j.1365-2702.2008.02724.x

Cited by 31 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is particularly important for patients who abruptly stop smoking due to admission to a smoke-free hospital and for patients who are likely to be taking multiple medications (Hughes, 1993;Schaffer et al, 2009).…”

Section: Provision Of Pharmacotherapymentioning

confidence: 99%

“…When patients stop smoking, staff need to review prescribed drug regimens and adjust or monitor drugs whose metabolism is affected by smoking cessation (Schaffer, Yoon, & Zadenzensky, 2009). This is particularly important for patients who abruptly stop smoking due to admission to a smoke-free hospital and for patients who are likely to be taking multiple medications (Hughes, 1993;Schaffer et al, 2009).…”

Section: Provision Of Pharmacotherapymentioning

confidence: 99%

See 1 more Smart Citation

Treating nicotine dependence in mental health hospitals

Wye

Bowman

Wiggers

et al. 2011

Mental Health and Substance Use

View full text Add to dashboard Cite

Although guidelines for the treatment of nicotine dependence have been implemented in general hospital settings, treatment does not occur systematically in mental health hospitals. A number of barriers to treatment exist, including ambivalent staff attitudes, the prevalence of staff who smoke, a lack of education and training in nicotine dependence treatment, a lack of nicotine replacement therapy use and knowledge of referral options post discharge and a lack of total smoking bans. Evidence from general hospital settings provides guidance on how to overcome these barriers. A first step is the implementation of total smoking bans. Further, evidence-based clinical practice guidelines and models of care need to be developed, melding the complexities of mental health and nicotine dependence treatment. Clinical systems in hospitals that support the provision of nicotine dependence treatment need to be enhanced. Finally, much more research on interventions is required to provide further evidence of what works.

show abstract

Section: Provision Of Pharmacotherapymentioning

confidence: 99%

Section: Provision Of Pharmacotherapymentioning

confidence: 99%

Treating nicotine dependence in mental health hospitals

Wye

Bowman

Wiggers

et al. 2011

Mental Health and Substance Use

View full text Add to dashboard Cite

show abstract

“…Immediate dose reductions should be considered for drugs with a narrow therapeutic index-such as olanzapine, clozapine, and warfarin-to avoid drug toxicity. 29 Patients should also be advised to reduce caffeine intake.…”

Section: Effects Of Smoking and Smoking Cessation On Drug Metabolismmentioning

confidence: 99%

Supporting smoking cessation

Zwar

Mendelsohn

Richmond

2014

BMJ

View full text Add to dashboard Cite

Despite the decrease in prevalence of tobacco use in developed countries, smoking remains the most common preventable cause of disease and death in the world today. Advice on smoking cessation from doctors and other health professionals has been shown to improve quit rates and is highly cost effective.1 Given the importance to health of tobacco use and the benefits of cessation, every doctor should encourage attempts to stop, be able to provide brief smoking cessation intervention, and be aware of referral options (see box 1). Over the past decade there have been advances in the science and practice of smoking cessation support. These include new medicines to treat nicotine dependence, new ways of using existing medicines, and increasing use of technology to support behavioural change. This review provides an update on evidence based approaches to maximise the effectiveness of the treatment of tobacco dependence.

show abstract

“…Its interactions with drugs and diseases have been extensively studied, and numerous literature reviews have been published [2][3][4][5][6][7]. However, the relevant information in US Food and Drug Administration (FDA)-approved drug labelling has not been analysed.…”

Section: Introductionmentioning

confidence: 99%

Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling

Shi

2015

Clin Pharmacokinet

View full text Add to dashboard Cite

The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to guide medication usage. This study aimed to provide a comprehensive review of drugs or diseases interacting with smoking, as presented in all US drug labelling. The 62,857 drug labels deposited in the FDA Online Label Repository were searched using the keywords 'smoke', 'smoker(s)', 'smoking', 'tobacco' and 'cigarette(s)' on 19 June 2014. The resultant records were refined to include only human prescription drug labelling, for manual examination. For 188 single-active-ingredient drugs and 36 multiple-active-ingredient drugs, the labelling was found to contain smoking-related information. The pharmacokinetics of 29 and 21 single-active-ingredient drugs were affected and unaffected, respectively, by smoking. For the remaining drugs, the provided information related to smoking affecting efficacy, safety or diseases but not pharmacokinetics. Depending on the nature of specific drugs, the perturbation in pharmacokinetic parameters in smokers ranged from 13 to 500%, in comparison with non-smokers. Dosage modifications in smokers are necessary for four drugs and may be necessary for six drugs, but are unnecessary for seven drugs although the pharmacokinetic parameters of four of them are affected by smoking. Cigarette smoking is a risk factor for 16 types of diseases or adverse drug reactions. For one single-active-ingredient contraceptive drug and 10 multiple-active-ingredient contraceptive drugs, a black box warning (the FDA's strongest safety warning) is included in the labelling for increased risks of heart attacks and strokes in female smokers, and "women are strongly advised not to smoke" when using these drugs. This study presents the first comprehensive overview of cigarette smoking interacting with drugs and/or diseases, as presented in US drug labelling.

show abstract

A review of smoking cessation: potentially risky effects on prescribed medications

Cited by 31 publications

References 32 publications

Treating nicotine dependence in mental health hospitals

Treating nicotine dependence in mental health hospitals

Supporting smoking cessation

Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling

Contact Info

Product

Resources

About